Biopharma Advances Alcohol-Associated Hepatitis Trial, Receives Analgesia Drug Approval

Retrieved on: 2021-03-17 17:26:15

Tags for this article:

Finance

Money

Financial services

Primary dealers

Subprime mortgage crisis

United States corporate law

DURECT Corp.

Ed Arce

Click the tags to see associated articles and topics

Biopharma Advances Alcohol-Associated Hepatitis Trial, Receives Analgesia Drug Approval. View article details on hiswai:

Excerpt

Regarding DUR-928, the first patient was dosed for the biopharma's Phase 2b AHFIRM trial in patients with severe alcohol-associated hepatitis (AH), ...

Article found on: www.streetwisereports.com

View Original Article